Louisiana Healthcare Connections Policies and Procedures Updates
Date: 09/25/23
Louisiana Healthcare Connections is sharing with providers the below policies and procedures that were developed and/or revised; posted for public comment and approved by LDH in accordance with La. R.S. 46:460.54. Non-material revisions do not require LDH approvals.
Please share this notice with other members of your practice and office staff as necessary.
These guidelines will be implemented 30 days from the date of this notice and will be posted on our Clinical & Payment Policies page.
Policy & Procedure # | Policy & Procedure Title | New, material revisions, non-material revisions |
|---|
LA.CP.MP.510c | Community Brief Crisis Support | Material |
LA.CP.MP.184c | Invasive and Non-Invasive Home Ventilators | Material |
LA.CP.MP.50c | Outpatient Testing For DOA | Material |
LA.PP.025 | Pulse Oximetry with Office Visits | Material |
LA.PP.051 | EM Medical Decision Making | Material |
LA.PP.032 | Supplies billed on Same day as Surgery | Non-material |
LA.PP.033 | Multiple CPT Code Replacement | Non-material |
LA.PP.034 | Modifier DOS Validation | Non-material |
LA.PP.038 | Inpatient Consultation | Non-material |
LA.PP.047 | Transgender Related Services | Non-material |
LA.PP.056 | Urine Specimen Validity Testing | Non-material |
LA.PP.060 | Not Med Nec Inpatient Services | Non-material |
LA.PHAR.591 | Tofersen (BIIB067) | New |
LA.PHAR.592 | Beremagene Geperpavec (Vyjuvek) | New |
LA.PHAR.600 | Trofinetide (NNZ-2566) | New |
LA.PHAR.433 | Polatuzumab Vedotin-piiq (Polivy) | New |
LA.PHAR.455 | Enfortumab Vedotin-ejfv (Padcev) | New |
LA.PHAR.465 | Teprotumumab (Tepezza) | New |
LA.PHAR.475 | Sacituzumab govitecan-hziy (Trodelvy) | New |
LA.PHAR.491 | Setmelanotide (Imcivree) | New |
LA.PHAR.503 | Sutimlimab-jome (Enjaymo) | New |
LA.PHAR.506 | Antithymocyte Globulin (Atgam, Thymoglobulin) | New |
LA.PHAR.581 | Faricimab (Vabysmo) | New |